65463-97-0

Usage

Functional group

Carbonyl chloride

Substituent

Phenyl

Chemical structure

A piperazine ring with a carbonyl chloride group attached to position 1 and a phenyl group attached to position 4

Reactivity

Highly reactive

Uses

Organic synthesis, pharmaceutical research, production of pharmaceuticals (antihistamines, antipsychotics, and antiemetic agents), building block in the synthesis of other organic compounds, and as a reagent in chemical reactions

Importance

Valuable and useful chemical in the field of organic chemistry and drug development due to its versatile reactivity and pharmaceutical applications.

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 934703-82-9 6-fluoro-1,2-bis(4-phenylpiperazine-1-carbonyl)-1,2-dihydroindazol-3-one 
• 934703-81-8 6-fluoro-1-(4-phenylpiperazine-1-carbonyl)-1H-indazol-3-yl 4-phenylpiperazine-1-carboxylate 
• 1233852-81-7 (4-phenyl-1H-imidazol-1-yl)(4-phenylpiperazin-1-yl)methanone 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities

Cdc37 associates kinase clients to Hsp90 and promotes the development of cancers. Celastrol, a natural friedelane triterpenoid, can disrupt the Hsp90-Cdc37 interaction to provide antitumor effects. In this study, 31 new celastrol derivatives, 2a - 2d , 3a - 3g , and 4a - 4t , were designed and synthesized, and their Hsp90-Cdc37 disruption activities and antiproliferative activities against cancer cells were evaluated. Among these compounds, 4f , with the highest tumor cell selectivity (15.4-fold), potent Hsp90-Cdc37 disruption activity (IC50= 1.9 μM), and antiproliferative activity against MDA-MB-231 cells (IC50= 0.2 μM), was selected as the lead compound. Further studies demonstrated 4f has strong antitumor activities both in vitro and in vivo through disrupting the Hsp90-Cdc37 interaction and inhibiting angiogenesis. In addition, 4f exhibited less toxicity than celastrol and showed a good pharmacokinetics profile in vivo. These findings suggest that 4f may be a promising candidate for development of new cancer therapies.

MEDICAMENTS

A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.